Epidemiology, Real-World Treatment Patterns, and Patient Outcomes of Primary Advanced or Recurrent Endometrial Cancer in Germany between 2015 and 2021
The analysis of the German claims data produced contemporary epidemiologic estimates for advanced or recurrent endometrial cancer. Treatments were aligned with guideline recommendations during the study period, with tumor testing yet to enter mainstream practice.
Authors
- Florian M. Karl (ORCID: https://orcid.org/0000-0002-3155-4941)
- Fabienne Schochter (ORCID: https://orcid.org/0000-0003-3675-6494)
- Andreas Fuchs (ORCID: https://orcid.org/0000-0003-0236-0811)
- Johanna I. Lutter (ORCID: https://orcid.org/0000-0002-0159-4862)
- Antje Mevius (ORCID: https://orcid.org/0000-0002-9556-6693)
- T Wilke
- Liam Tuffy
Institutions
- Wismar University of Applied Sciences (DE)
- GlaxoSmithKline (Germany) (DE)
- University Hospital Ulm (DE)
Publication Details
- Journal
- Oncology Research and Treatment
- Published
- 2024-11-27
- DOI
- https://doi.org/10.1159/000542773
- Citations
- 1
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.58